Replies to post #1748 on Generex Biotechnology Corp. (fka GNBTQ)

[bapi]

A company roadmap of where it is heading:

1. Moving from R&D to market penetration with their OTC drugs.

2. Enjoying sales of OTC products to offset their operational expenses monthly.

3. Using revenues from sales of its OTC to expand Oralyn Globally.

4. After Oralyn is globally and approved in US and Canada, they will expend all energy to develop Breast Cancer, Prostate Cancer, Cervical, and Flu drugs to market.

5.Overseas markets are awaiting Oralyn, approvals from FDA . When approved will expand to EUROPE, MIDDLE EAST, CANADA, and many parts of the Globe simultaneously.

6.Reducing expenses, creating a market Globally for all its products.

7.Reducing float and OS , by repurchasing shares in Company.

8. No more dilluting shares, may partner with others and receive royalties. No buyout only if the price is right.